Arspura Showcases a New Standard for Healthy Kitchen Living at CES 2026 
Xenon to Report Q3 2025 Financial Results on November 3, 2025
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company...
Xenon to Report Q3 2025 Financial Results on November 3, 2025
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company...
Xenon to Report Q3 2025 Financial Results on November 3, 2025
VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company...
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival...
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival...
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival...
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET
MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences...
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET
MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences...
RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET
MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences...
KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia
KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia At Global Health Exhibition 2025 held...
KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia
KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia At Global Health Exhibition 2025 held...
KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia
KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia At Global Health Exhibition 2025 held...
Tria Federal Joins ServiceNow Partner Program to Power Digital Transformation in Government
Tria Federal joins ServiceNow Partner Program to power digital transformation in government Tria Federal (Tria) has joined the ServiceNow Partner...
Tria Federal Joins ServiceNow Partner Program to Power Digital Transformation in Government
Tria Federal joins ServiceNow Partner Program to power digital transformation in government Tria Federal (Tria) has joined the ServiceNow Partner...
Tria Federal Joins ServiceNow Partner Program to Power Digital Transformation in Government
Tria Federal joins ServiceNow Partner Program to power digital transformation in government Tria Federal (Tria) has joined the ServiceNow Partner...
Creative Medical Technology Holdings Issues Letter to Shareholders
Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026PHOENIX, Oct....
Creative Medical Technology Holdings Issues Letter to Shareholders
Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026PHOENIX, Oct....
Creative Medical Technology Holdings Issues Letter to Shareholders
Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026PHOENIX, Oct....
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to...
Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®
BRISBANE, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to...